Sandusky, OH, Nov. 17, 2021 — McapMediaWire –– PAO Group, Inc. (OTC PINK: PAOG) today confirmed plans to add multiple new pharmaceutical products to its development pipeline in addition to its ongoing development of its RespRx CBD pharmaceutical for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
The company has been conducting an in-depth review of its current RespRx CBD pharmaceutical development project with its CRO partner, industry consultants and other pharmaceutical firms in an effort to explore various opportunities to accelerate and diversify development.
As the in-depth review continues, PAOG has now identified derivate opportunities from its research to launch additional pharmaceutical product development projects. The identified opportunities PAOG plans to pursue have fast-track potential and it now appears some of the opportunities have the potential to generate substantial revenue rapidly as early as next year in 2022.
PAOG anticipates releasing more information on specific opportunities sin the coming weeks.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.